Rusfertide still needs to be Verified
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
FDA red and green lights: February 2026
The month saw the first commissioner's priority voucher approval in oncology.
Spurned by Sanofi, Orano turns to Roche
The first fruit of a long-standing deal with Roche enters phase 1 in March.
Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
ASCO-GU 2026 – gauging Welireg’s double win
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
